amplifiers all target the promotion of CFTR production (2, 5), Zaman and colleagues focus on reducing ubiquitination and proteasomal degradation, increasing CFTR trafficked to the cell membrane (6) . The F508del CFTR mutation impairs protein folding and assembly, and is detected by the cells' quality control (QC) system. Polyubiquitination of defective CFTR leads to its extraction from the endoplasmic reticulum (7) . Detection of defective CFTR in the cytoplasm is performed by cHSP-70 (8) . cHSP-70 interacts with the E3 ligase carboxy terminus of heat shock protein 70-interacting protein (CHIP), which in association with the E2 ligase UbcH5a effects ubiquitination and transport of misfolded CFTR for degradation by the cells' QC system (the ubiquitin-proteasome system) (7, 8) . Targeted therapies could inhibit ubiquitin-dependent degradation of CFTR, shielding it from the ubiquitin-proteasome system machinery, and CHIP inhibition has been identified as a potential pharmacological target (9) (Figure 1 ).
Nitric oxide (NO) synthases are abundant in the respiratory epithelium and are essential for the formation of stable bioactive S-nitrosothiols (SNOs), which are important for cellular signaling, -NO transfer, and regulation of protein function (10) . Dysregulation of SNO formation is implicated in multiple respiratory diseases (10), including CF. Nitrosylation inhibits E3 ligases (11) and increases CFTR maturation (12) and chloride transport (13) in CF airway epithelial cells. Zaman and colleagues hypothesized that SNOs could inhibit CFTR proteasomal degradation through S-nitrosylation-dependent inhibition of CHIP. They showed CHIP expression in primary cells and bronchial cell lines, with dose-dependent S-nitrosylation of CHIP after treatment with S-nitrosoglutathione (GSNO), which reduced CHIP expression and activity. This led to a reduction in CHIP-CFTR and to decreases in CFTR ubiquitination, allowing F508 del CFTR to escape the endoplasmic reticulum QC system and traffic to the cell membrane. This reveals, for the first time, the mechanism behind the effect of S-nitrosylation on CFTR expression ( Figure 1 ). Of all SNOs tested, S-nitrosoglutathione diethyl ester (GNODE) showed the highest effect on CFTR maturation, but in the current study this was tested only in cell monolayers. To progress toward CFTR-modulating therapies, cellpermeable GSNO analogs, including GNODE, should be used to test whether these findings can be replicated in differentiated pseudostratified epithelium. The bioavailability and bioactivation of SNOs may be lower in pseudostratified epithelium, potentially reducing the overall effect of GSNO on CFTR expression (14) .
Modulation of the QC system may increase CFTR trafficked to the cell surface (6, 7), but the impact on CFTR-dependent chloride transport and later denaturation requires further investigation both in vitro and in vivo (2, 5) . Previous in vivo studies using SNOs in CF focused on their antiinflammatory, smooth-muscle relaxant and bronchodilatory potential (15) . A randomized trial of inhalational GSNO demonstrated tolerability, but only modest effects on oxygen saturation were seen (15) . Although Zaman and colleagues focus on the potential of GSNO as an inhalational agent, all current CFTR modulators are delivered orally to permit systemic CFTR modulation (3, 4) . CF is a multisystem disease and the systemic effects of CFTR modulators contribute significantly to their clinical benefits (1) (2) (3) (4) (5) . Future studies are needed to investigate pharmacological modifications of QC systems and their effects on proteasomal degradation of CFTR, which may differ depending on cell-and tissue-dependent expression (7). With nitrosylation of CHIP being dose dependent (6), optimizing therapeutic ranges across multiple cell types and individuals will be challenging. Furthermore, any adverse effects of nitrosative stress (excessive NO/reactive oxygen species) that can contribute to NOinduced neurotoxicity (11) must be identified.
This study highlights a novel therapeutic target, nitrosylation of CHIP, with the potential to provide an innovative means of modulating CFTR. Selective modification of the QC machinery remains an attractive approach. Further exploration of therapeutic targets in the pathway identified by Zaman and colleagues may lead to the generation of systemic therapies that benefit PWCF. In combination with other CFTR modulators, this could further optimize clinical benefits in the future (Figure 1 ). Zaman and colleagues may have brought a potential new player to the table, and further study will determine what impact this has on those already there. n . CFTR correctors enhance CFTR transcriptional and translational output, allowing for some CFTR to be trafficked to the apical surface. Here, CFTR potentiators enhance the channel gating, resulting in chloride conductance (right). In the future, CFTR amplifiers could increase the CFTR substrate available for CFTR correctors. Alternatively, nitrosylation of CHIP (nitrosothiols) leads to reduced CHIP expression and activity, allowing misfolded CFTR to escape the quality control system, enhancing CFTR maturation. The addition of CFTR potentiators may provide further benefits. CHIP-NO = nitrosylated CHIP; cHSP-70 = cytosolic heat protein-70; Cl 2 = chloride anion; SNO = S-nitrosothiols; UPS = ubiquitin-proteasome system; Sp1/Sp3 = transcription factors specificity protein 1/ specificity protein 3. 
